Form 4: H.B. Fuller Executive VP and CFO, John J. Corkrean, Reports Changes in Beneficial Ownership

Sentiment:

SEC Form 4


John J. Corkrean, Executive VP and CFO of H.B. Fuller, filed a Form 4 detailing changes in his beneficial ownership of the company's stock, including the acquisition of phantom units and holdings of employee stock options and restricted stock units.

Summary

  • On May 28, 2024, John J. Corkrean, Executive VP and CFO of H.B. Fuller, reported changes in his beneficial ownership of the company's securities.
  • The report details the acquisition of 98.79 phantom units on May 24, 2024, at a price of $79.40.
  • Corkrean directly owns 47,187 shares of common stock.
  • He also holds various employee stock options with exercise prices ranging from $43.48 to $77.72 and expiration dates between 2026 and 2034.
  • Additionally, he possesses restricted stock units that convert into common stock on a 1-for-1 basis, vesting in three annual installments.
  • The report includes holdings of 16,672 shares from options exercisable on May 17, 2017, with an exercise price of $43.48, expiring on May 17, 2026.
  • He also holds 41,208 shares from options exercisable on January 24, 2020, with an exercise price of $45.05, expiring on January 24, 2029.
  • The report also includes holdings of 48,309 shares from options exercisable on January 24, 2021, with an exercise price of $48.35, expiring on January 24, 2030.
  • The report also includes holdings of 23,696 shares from options exercisable on January 26, 2018, with an exercise price of $50.1, expiring on January 26, 2027.
  • The report also includes holdings of 38,376 shares from options exercisable on January 27, 2022, with an exercise price of $51.89, expiring on January 27, 2031.
  • The report also includes holdings of 21,834 shares from options exercisable on January 25, 2019, with an exercise price of $53.57, expiring on January 25, 2028.
  • The report also includes holdings of 22,312 shares from options exercisable on January 24, 2024, with an exercise price of $68.17, expiring on January 24, 2033.
  • The report also includes holdings of 21,997 shares from options exercisable on January 24, 2023, with an exercise price of $72.94, expiring on January 24, 2032.
  • The report also includes holdings of 24,774 shares from options exercisable on January 26, 2025, with an exercise price of $77.72, expiring on January 26, 2034.
  • The report also includes holdings of 1,117.01 restricted stock units vesting on January 24, 2023, expiring on January 24, 2025.
  • The report also includes holdings of 2,509.32 restricted stock units vesting on January 24, 2024, expiring on January 24, 2026.
  • The report also includes holdings of 4,164.64 restricted stock units vesting on January 26, 2025, expiring on January 26, 2027.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing detailing changes in beneficial ownership, with no explicitly positive or negative implications.

Positives

  • The reporting person's continued holding of a significant amount of company stock and options could be interpreted as a positive sign of confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Monitoring these filings can offer insights into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

  • Executive compensation packages, including stock options and restricted stock units, are common across publicly traded companies like H.B. Fuller.
  • Companies such as 3M, Dow, and DuPont also utilize similar equity-based compensation to align executive interests with shareholder value.
  • The vesting schedules and exercise prices of the options are typical for executive compensation plans in the industry.

Stakeholder Impact

  • The filing provides transparency to shareholders regarding the executive's holdings and potential alignment of interests.

Key Dates

DateDescription
05/17/2017Date of employee stock option grant with an exercise price of $43.48, expiring on May 17, 2026.
01/26/2018Date of employee stock option grant with an exercise price of $50.1, expiring on January 26, 2027.
01/25/2019Date of employee stock option grant with an exercise price of $53.57, expiring on January 25, 2028.
01/24/2020Date of employee stock option grant with an exercise price of $45.05, expiring on January 24, 2029.
01/24/2021Date of employee stock option grant with an exercise price of $48.35, expiring on January 24, 2030.
01/27/2022Date of employee stock option grant with an exercise price of $51.89, expiring on January 27, 2031.
01/24/2023Date of employee stock option grant with an exercise price of $72.94, expiring on January 24, 2032, and restricted stock units vesting on this date, expiring on January 24, 2025.
01/24/2024Date of employee stock option grant with an exercise price of $68.17, expiring on January 24, 2033, and restricted stock units vesting on this date, expiring on January 24, 2026.
01/26/2025Date of employee stock option grant with an exercise price of $77.72, expiring on January 26, 2034, and restricted stock units vesting on this date, expiring on January 26, 2027.
05/24/2024Transaction date for the acquisition of phantom units.
05/28/2024Date of the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.